Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 41.94 Billion | USD 71.46 Billion | 6.10% | 2023 |
The global single-photon emission computed tomography market size was worth around USD 41.94 billion in 2023 and is predicted to grow to around USD 71.46 billion by 2032 with a compound annual growth rate (CAGR) of roughly 6.10% between 2024 and 2032.
A single-photon emission computed tomography (SPECT) scan is an integration of radioactive trace and computed tomography (CT). It is a medical imaging system that scans blood flow to organs and tissues. SPECT is used across several medical procedures as it is helpful in diagnosing conditions such as stroke, seizures, infections, stress fractures, and spinal tumors. In single-photon emission computed tomography, the tracer allows medical professionals to see blood flow regulation in the body. Radiolabeled tracers are first injected into the bloodstream before the SPECT scan. The gamma rays emitted by the tracer are detected by a CT scanner.
The information thus collected through the computer is displayed on CT cross-sections that can be added back together to create a 3-dimensional image of the brain. The most common isotopes used in SPECT are technetium-99m, iodine-123, fluorine-18, thallium-201, and xenon-133. Chemicals and drugs of several types can be labeled with these isotopes for medical imaging. SPECT scan is not recommended for nursing or pregnant women. The rise in healthcare expenditure across the globe is driving the market demand rate. However, risks associated with SPECT may limit the single-photon emission computed tomography industry's expansion rate.
Growing healthcare expenditure worldwide to drive the market growth rate
The global single-photon emission computed tomography market is expected to grow due to the rising healthcare expenditure globally. The surging population rate along with the exponential rise in the number of patients worldwide is driving healthcare expenses. There is an urgent demand for equal distribution of quality healthcare globally. The most common medical concerns often recorded worldwide are related to cardiovascular diseases (CVDs). These conditions directly affect the health of the blood vessels and heart. According to the Cleveland Clinic, around 50% of the American population suffers from at least one heart-related condition. The most common CVDs are coronary artery disease, valve disease, arrhythmia, peripheral artery disease, pericardial disease, and deep vein thrombosis (DVT). In addition to this, healthcare access in economically striving countries is at an extreme low. This has resulted in international welfare organizations and other nations investing heavily in ensuring healthcare reaches unprivileged sections of society. In an exceptional show of unity, around 14 African countries pledged a total of USD 45 million to the World Health Organization (WHO) Investment Round as a means to contribute to global healthcare infrastructure.
Growing trend of preventive medicine may generate exceptional growth possibilities
The application of single-photon emission computed tomography scans is expected to be influenced by the rising trend and investment toward preventive medicine. It deals with the use of available healthcare solutions to prevent diseases. SPECT is helpful to medical professionals in assessing risk factors and drawing preventive measures. Single-photon emission CT scans can be used for evaluating heart conditions and potential neurological conditions. Additionally, cancer prevention can be achieved using solutions available in the global single-photon emission computed tomography market.
High cost of SPECT technology will limit the industry’s growth rate
The global industry for single-photon emission computed tomography is expected to be restricted due to the high cost of technology. Simple CT scans are expensive treatments. The cost increases further due to the use of radioisotopes, which are produced using specialized development techniques. Storage and application of radioisotopes require sophisticated solutions. The average cost of a SPECT scan in the US is around USD 1000 to USD 4100 without insurance.
Advancements in SPECT technology will generate more growth opportunities during the projection period
The global single-photon emission computed tomography market is expected to generate more growth opportunities due to technological advancements in the industry. In June 2022, Siemens Healthineers, a leading player in the industry, announced receiving US Food & Drugs Administration (FDA) clearance for Symbia Pro. specta. It is made using highly sophisticated SPECT imaging and CT technologies. One of the key features of the device is the use of low-dose CT of up to 64 slices offering excellent detail and automated workflow. The surge in investment in molecular imaging techniques will be helpful in driving the market demand rate. In June 2024, Jubilant Radiopharma announced plans to invest around USD 50 million for the expansion of the Positron Emission Tomography (PET) radiopharmaceutical manufacturing capacity. The company will use the fund to construct nearly 6 manufacturing facilities across the United States. The development of hybrid systems SPECT/CT will also create higher acceptance by market consumers. In July 2024, patients in Nanaimo, Canada region, were provided access to a highly advanced novel hybrid Gamma SPECT-CT camera. Almost 200 patients have received the benefits of the technology at the Nanaimo Regional General Hospital (NRGH) since its introduction in March 2024.
Risks associated with the use of radioisotopes will challenge the market expansion rate
The global single-photon computed tomography industry is expected to be challenged by the risk of using radioisotopes during diagnosis and treatment procedures. While radioisotopes are used in limited quantities, any negligence in dosage can lead to severe health implications. Additionally, certain patients may have an allergic reaction to the radioactive materials, further worsening the existing medical condition.
The global single-photon emission computed tomography market is segmented based on application, product, type, and region.
Based on the application, the global market segments are neurology, cardiology, oncology, and others. In 2023, the highest growth was observed in the neurology segment. Medical research suggests that seizures are mainly associated with epilepsy, a neurological disorder. According to Mayo Clinic, more than 3 million people in the US have epilepsy. It is the fourth most common neurological disorder prevalent in the country. The use of SPECT technology is also registered in the cardiology segment.
Based on product, the global single-photon emission computed tomography industry is divided into SPECT/CT and single imaging gamma cameras.
Based on the type, the global market segments are hybrid SPECT systems and standalone SPECT systems. In 2023, the highest growth was observed in the hybrid SPECT systems segment. Hybrid single-photon emission computed tomography scans show clearer images. Moreover, the technical capabilities of hybrid SPECT are better than standalone systems. The surge in the number of patients with chronic conditions will drive segmental demand. As per official statistics, more than 11% of the US population is diabetic.
Report Attributes | Report Details |
---|---|
Report Name | Single-photon Emission Computed Tomography Market |
Market Size in 2023 | USD 41.94 Billion |
Market Forecast in 2032 | USD 71.46 Billion |
Growth Rate | CAGR of 6.10% |
Number of Pages | 231 |
Key Companies Covered | Beijing Hamamatsu Photon Techniques, Canon Medical Systems, Siemens Healthineers, Mediso Medical Imaging Systems, NucLeomed, Digirad Corporation, SurgicEye GmbH, GE Healthcare, Bracco Imaging, Philips Healthcare, DDD-Diagnostic, Spectrum Dynamics, MILabs B.V., MIE America, Cardiarcs Ltd., and others. |
Segments Covered | By Application, By Product, By Type, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to register the highest growth during the projection period
The global single-photon emission computed tomography market is projected to be led by North America during the projection period. The US will deliver the highest revenue in the regional market. Growth in North America will be driven by the presence of a highly sophisticated and robust healthcare infrastructure. The US, for instance, is a leading region in terms of medical tourism for several types of serious medical conditions. The increasing investments in cancer research, including early detection of systems and subsequent treatment, will promote the use of SPECT in the region.
Europe is expected to deliver significant revenue in the single-photon emission computed tomography industry over the projection period. The regional market is driven by the growing demand for preventive medicine. European nations have shown greater interest in deploying sources and technologies that can aid disease prevention. SPECT scans have proven beneficial in delivering preventive medical care. The growing innovation rate in terms of advancements in SPECT technology will further promote regional market expansion. The rise in the geriatric population, patients with chronic medical conditions, and increased healthcare expenses will also work in favor of growth in Europe.
The global single-photon emission computed tomography market is led by players like:
By Application
By Product
By Type
FrequentlyAsked Questions
A single-photon emission computed tomography (SPECT) scan is an integration of radioactive trace and computed tomography (CT).
The global single-photon emission computed tomography market is expected to grow due to the rising healthcare expenditure globally.
According to study, the global single-photon emission computed tomography market size was worth around USD 41.94 billion in 2023 and is predicted to grow to around USD 71.46 billion by 2032.
The CAGR value of the single-photon emission computed tomography market is expected to be around 6.10% during 2024-2032.
The global single-photon emission computed tomography market is projected to be led by North America during the projection period.
The global single-photon emission computed tomography market is led by players like Beijing Hamamatsu Photon Techniques, Canon Medical Systems, Siemens Healthineers, Mediso Medical Imaging Systems, NucLeomed, Digirad Corporation, SurgicEye GmbH, GE Healthcare, Bracco Imaging, Philips Healthcare, DDD-Diagnostic, Spectrum Dynamics, MILabs B.V., MIE America and Cardiarc Ltd.
The report explores crucial aspects of the single-photon emission computed tomography market including a detailed discussion of existing growth factors and restraints while also browsing future growth opportunities and challenges that impact the market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed